EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This phase II study will investigate the activity and safety of radionuclide 177Lu-PSMA therapy versus 177Lu-PSMA in combination with Ipilimumab and Nivolumab in patients with metastatic castrate resistant prostate cancer (mCRPC).
Epistemonikos ID: b825f4c557dec499e6550b1317f07ca08cf812b7
First added on: May 09, 2024